Examination of clinical outcomes in patients with autoimmune disease and diffuse large B cell lymphoma Público

Abstract

Background: Severe immune dysregulation as seen in autoimmune (AI) disease is known to act as a significant risk factor for diffuse large B cell lymphoma (DLBCL), but little is known about the demographics or clinical outcomes of DLBCL that arises in the setting of AI disease.

Patients and Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database for patients diagnosed 2002-2009 linked to their Medicare claims data through 2011 to characterize presentation, treatment, and survival patterns in DLBCL patients, including those with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), and other B cell-mediated AI diseases. Kaplan-Meier curves and Cox proportional hazards models were generated to examine the effect of concurrent AI disease diagnosis on overall survival (OS) and lymphoma-related survival (LRS). Multivariable logistic regression models were employed to investigate the relationships between patient characteristics and discrete survival endpoints.

Results: Patients with DLBCL and AI disease were more commonly female, but patients with DLBCL and RA, SLE, SS, or other B cell AI diseases did not differ from other DLBCL patients in any other baseline presenting features and received similar first-line treatments. Patients with concomitant RA and DLBCL had decreased LRS compared to patients without AI disease (hazard ratio 1.52, 95% confidence interval 1.03– 2.22). There was also a trend towards decreased LRS in patients with SLE and DLBCL compared to all other groups, but this difference was not statistically significant in this cohort.

Conclusions: In this retrospective claims-based cohort of older patients with DLBCL, concomitant AI disease was uncommon and was more likely to occur in female DLBCL patients, which likely reflects the higher incidence of AI disease in women. The possibility of lower LRS for RA and SLE patients should be explored in future studies.

Table of Contents

TABLE OF CONTENTS

 

 

INTRODUCTION……………………………………………………………………….. 1

 

BACKGROUND..……………………………………………………………………….. 3

 

METHODS………………………………………………………………………............. 7

 

RESULTS……...……………………………………………………………………….. 12

 

DISCUSSION…..……………………………………………………………………..... 15

 

REFERENCES...……………………………………………………………………….. 22

 

TABLES AND FIGURES……...………...…………………………………………….. 31

 

Table 1……...……………………….………………………………………….. 31

 

Table 2……...……………………….………………………………………….. 33

 

Table 3……...……………………….………………………………………….. 34

 

Table 4……...……………………….………………………………………….. 35

 

Table 5……...……………………….………………………………………….. 37

 

Table 6……...……………………….………………………………………….. 39

 

Table 7……...……………………….………………………………………….. 41

 

Figure 1……...……………………….……………………………………...….. 43

 

Figure 2……...……………………….……………………………...………….. 44

 

Figure 3……...……………………….…………………………………...…….. 46

About this Master's Thesis

Rights statement

• Permission granted by the author to include this thesis or dissertation in this repository. All rights reserved by the author. Please contact the author for information regarding the reproduction and use of this thesis or dissertation.

School	Laney Graduate School
Department	Clinical Research
Degree	M.S.
Submission	Master's Thesis
Language	English
Research Field	Health Sciences, Oncology
Palabra Clave	lymphoma
Committee Chair / Thesis Advisor	Flowers, Christopher, Emory University
Committee Members	Manatunga, Amita, Emory University Kempton, Christine, Emory University

Última modificación

Primary PDF

Thumbnail	Title	Date Uploaded	Actions
	Examination of clinical outcomes in patients with autoimmune disease and diffuse large B cell lymphoma ()	2018-04-02 13:15:35 -0400	Press to Select an action Download

Supplemental Files

Thumbnail	Title	Date Uploaded	Actions